Full-Time

Senior Clinical Project Manager

IQVIA

IQVIA

10,001+ employees

Analytics, technology, and clinical research services.

No salary listed

Nottingham, UK

In Person

Bachelor's

Category
Business & Strategy (1)
Required Skills
Microsoft Office
Word/Pages/Docs
Risk Management
Excel/Numbers/Sheets

Get referred to IQVIA

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Life Sciences or a related field is required.
  • More than 7 years of clinical research experience, including 4 years of project management experience, or an equivalent combination of education, training, and experience is required.
  • Advanced knowledge of the job area and broad knowledge of related job areas are required, typically obtained through advanced education combined with experience.
  • Knowledge of clinical trial conduct and the ability to apply applicable clinical research regulatory requirements, including ICH Good Clinical Practice and relevant local laws, regulations, and guidelines, to clinical trial conduct are required.
  • Broad protocol knowledge and therapeutic knowledge are required or desired for the role.
  • An understanding of the competitive environment and the ability to communicate and demonstrate value through IQVIA solutions are required.
  • Strong written and verbal communication skills, good command of the English language, and strong presentation skills are required.
  • Strong negotiation and customer management skills are required.
  • Strong problem-solving skills are required.
  • The ability to work through others to deliver results to appropriate quality and timeline metrics, monitor and manage performance, provide feedback, partner cross-functionally and with customers, and advance work effectively and efficiently is required.
  • Planning, time-management, and prioritization skills are required, including the ability to organize resources, set objectives, provide clear direction, plan activities in advance, and account for changing circumstances.
  • The ability to make decisions, bring clarity to disparate information, inform actions, and drive results is required.
  • The ability to handle conflicting priorities and work strategically to realize project goals is required.
  • Attention to detail and accuracy are required.
  • A results-oriented approach to work delivery and output, learning agility, and openness to keeping knowledge and skills current are required.
  • Good software and computer skills, including Microsoft Office applications such as Microsoft Word, Excel, and PowerPoint, are required.
  • The ability to establish and maintain effective working relationships with coworkers, managers, and clients, understand customer needs, provide customer service, mentor and train colleagues, and foster learning and knowledge sharing is required.
  • The ability to work across geographies with awareness and understanding of cultural differences is required.
  • An understanding of other IQVIA functions and their interrelationship with Project Leadership is required.
  • An understanding of project financials, including contractual obligations and implications, is required.
  • The ability to demonstrate IQVIA core competencies in client focus, collaboration, communication, innovation, and ownership is required.
Responsibilities
  • Participate in bid defense preparations and lead bid defense presentations with Business Development for multiple-service, multiple-country, and/or multiregional studies.
  • Develop integrated study management plans with the core project team.
  • Plan and execute clinical studies strategically according to the contract while optimizing delivery speed, quality, and cost, and ensuring consistent use of study tools, training materials, standard processes, policies, and procedures.
  • Set objectives for the core project team according to the agreed contract, strategy, and approach; communicate objectives effectively; and assess performance.
  • Collaborate with internal functional groups to support milestone achievement and manage study issues and obstacles.
  • Monitor progress against the contract and proactively prepare and present project information to internal and external stakeholders.
  • Deliver and manage medium-to-large, multiple, full-service, multiregional studies.
  • Manage positive and negative risks and contingencies proactively, and lead problem-solving and resolution efforts.
  • Identify quality risks and issues, respond to issues raised by project team members, and plan and implement appropriate corrective and preventative action plans.
  • Serve as the primary project contact with the customer and own relationships with key customer contacts.
  • Communicate and collaborate with IQVIA Business Development representatives as necessary.
  • Build the cross-functional project team and lead its efforts, manage cross-collaboration of the core team, and take responsibility for overall project delivery, milestone achievement, and management of study issues and obstacles.
  • Ensure the financial success of the project.
  • Forecast and identify opportunities to accelerate activities and bring revenue forward.
  • Identify changes in scope and manage the change-control process as necessary.
  • Identify and communicate lessons learned and best practices to promote continuous improvement.
  • Adopt corporate initiatives and changes and serve as a change advocate when necessary.
  • Provide input to line managers on project team members' performance relative to project tasks and support staff development.
  • Mentor less experienced project team members on assigned projects to support their professional development.
Desired Qualifications
  • Broad protocol knowledge and therapeutic knowledge are desired.

IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Its services combine deep clinical trial expertise with large datasets and analytics tools, delivered through the Connected Intelligence platform that links the healthcare ecosystem to generate insights while protecting patient privacy. The company differentiates itself by merging clinical research experience with expansive data resources and technology capabilities from its QuintilesIMS lineage, offering an integrated suite for faster research, development, and commercialization of medical treatments. IQVIA’s goal is to help pharmaceutical, biotech, and medical device companies, as well as researchers and governments, accelerate the development of new therapies and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1998

Get referred to IQVIA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 8.7% to $4.37 billion, and guidance increased again in July.
  • R&D bookings hit $3.15 billion, with backlog reaching $34.2 billion on June 30.
  • 19 of top 20 pharma companies use IQVIA AI, validating product-market fit.

What critics are saying

  • CNIL fined IQVIA France €5 million on May 26, 2026, for health-data warehouse breaches.
  • IQVIA is suing former executives after a Syneos client raid allegedly cost $180 million.
  • A California employment-discrimination case filed March 19, 2026, keeps workplace-liability headlines alive.

What makes IQVIA unique

  • IQVIA.ai, launched March 2026 with NVIDIA, embeds agentic AI into life-sciences workflows.
  • February 2026 Charles River asset deal expands end-to-end discovery from hit-to-lead through safety.
  • Its 34.2 billion backlog and 56-country DCRI collaboration lock in switching costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Flexible Work Hours

Paid Vacation

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
IQVIA Holdings Inc.
Aug 17th, 2026
IQVIA ranked No. 1 Pharmaceutical Technology provider by Everest Group.

IQVIA ranked No. 1 Pharmaceutical Technology provider by Everest Group. 08/17/2026 RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group's "Top 50(TM) Pharmaceutical Technology Providers" report for 2026. IQVIA earned the highest overall score among the 50 providers evaluated, receiving 96.8 out of 100. The ranking recognizes IQVIA's broad technology coverage across the pharmaceutical value chain and its ability to support complex, highly regulated life sciences environments. IQVIA was the only provider in the ranking with technology coverage across all six pharmaceutical value-chain areas assessed: drug discovery and research, clinical development, manufacturing operations, sales and marketing, supply chain and distribution and pharmacovigilance and safety. This breadth of coverage helps customers connect capabilities across the product lifecycle, make better decisions and execute more effectively. IQVIA combines proprietary data and content, deep life sciences expertise, advanced technology and longstanding experience operating in highly regulated, privacy-sensitive environments to help customers address complex challenges with greater confidence. Biopharma customers are looking for more than individual technologies. They demand solutions that work together and a partner that understands the realities of their business. To learn more about how IQVIA helps life sciences and healthcare organizations turn data, technology and AI into better outcomes, visit: www.iqvia.com. About Everest Group Everest Group is a leading global research firm helping business leaders make confident decisions. It guides clients through today's market challenges and strengthens their strategies by applying contextualized problem-solving to their unique situations. This drives maximized operational and financial performance and transformative experiences. The Everest Group's deep expertise and tenacious research focused on technology, business processes and engineering through the lenses of talent, sustainability and sourcing deliver precise and action-oriented guidance. Find further details and in-depth content at www.everestgrp.com. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. Kerri Joseph, IQVIA Investor Relations ([email protected]) +1.973.541.3558 Multimedia Files: Company's logo

GlobeNewswire
Aug 4th, 2026
IQVIA and Medera to advance cardiac gene therapy and human-based drug discovery.

IQVIA and Medera to advance cardiac gene therapy and human-based drug discovery. August 04, 2026 16:15 ET | Source: Medera Inc. RESEARCH TRIANGLE PARK, N.C. and BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) - IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms. The collaboration brings together IQVIA's global clinical trial and commercialization infrastructure with Medera's pioneering platforms: Sardocor, focused on developing disease-modifying gene therapies for difficult-to-treat cardiovascular diseases, and Novoheart, a leader in engineered human-based cardiac tissue for disease modelling and drug screening. Sardocor will leverage IQVIA's regulatory and trial execution expertise to advance its FDA-cleared, first-in-human AAV-based gene therapy programs. IQVIA will support patient recruitment, data quality and regulatory filings, including applications for expedited FDA designations. Novoheart's mini-Heart platform is already instrumental in securing IND and Fast Track designations and offers a predictive, human-based alternative to animal testing. The platform is expanding into multiple organ systems to support drug discovery and safety testing under the FDA Modernization Act 2.0. "By combining IQVIA's global expertise with Medera's mini-Heart platform and gene therapy programs, we can bring safer, more effective therapies to patients faster," said Ronald Li, Co-Founder, Chairman & CEO of Medera. "This collaboration expands our reach, while reinforcing the scientific and regulatory momentum around human-based drug discovery and cardiac gene therapy innovation." About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. About Medera Inc. Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing next-generation therapeutics. Medera operates via two business units: Sardocor, its clinical development arm advancing a pipeline of cardiac gene therapy trials (HFpEF, HFrEF, DMD-CM), and Novoheart, its preclinical subsidiary pioneering the world's first and award-winning "mini-Heart" technology for human-based disease modelling, drug discovery, and toxicity testing. Novoheart's platforms have already supported FDA IND and Fast Track designations, and the company is advancing a broader pipeline of gene therapy, cell therapy, and small molecule candidates. For more information, visit www.medera.bio. | Contacts: | / | | Ally Stubin ICR Healthcare Media Relations 646-667-1861 [email protected] Stephanie Carrington ICR Healthcare Investor Relations 646-277-1282 [email protected] | Alissa Maupin IQVIA Media Relations 919-923-6785 [email protected] Kerri Joseph IQVIA Investor Relations 973-541-3558 [email protected] |

MarketBeat
Jul 30th, 2026
IQVIA Holdings Inc. (NYSE:IQV) receives consensus rating of "Moderate Buy" from brokerages.

IQVIA Holdings Inc. (NYSE:IQV) receives consensus rating of "Moderate Buy" from brokerages. July 30, 2026 Key points. * Analysts maintain a bullish outlook: Sixteen brokerages assign IQVIA a consensus "Moderate Buy" rating, with 13 buys and three holds. The average 12-month price target is approximately $241.88, while several firms recently raised targets as high as $287. * Second-quarter performance exceeded expectations: Adjusted earnings were $3.15 per share versus the $3.03 consensus, while revenue increased 8.7% year over year to $4.37 billion. IQVIA also raised its fiscal 2026 earnings guidance to $12.80-$13.00 per share and cited record R&D bookings and a growing backlog. * Shares are near their 52-week high: IQVIA opened at $247.84, compared with a 52-week high of $251.36, and institutional investors own 89.62% of the stock. The company also has authorization for a $2 billion share repurchase program, covering up to 6.8% of outstanding shares. * Five stocks to consider instead of IQVIA. IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has received an average rating of "Moderate Buy" from the sixteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $241.8824. Several analysts have commented on IQV shares. Mizuho increased their target price on IQVIA from $215.00 to $230.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Barclays reaffirmed an "overweight" rating on shares of IQVIA in a report on Tuesday. Robert W. Baird lifted their price objective on IQVIA from $252.00 to $287.00 and gave the stock an "outperform" rating in a report on Wednesday. HSBC reissued a "buy" rating and issued a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Finally, Stifel Nicolaus raised their price target on shares of IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a report on Wednesday. Key stories impacting IQVIA. Here are the key news stories impacting IQVIA this week: * Positive Sentiment: Second-quarter results exceeded expectations: IQVIA reported adjusted earnings of $3.15 per share versus the $3.03 consensus estimate, while revenue rose 8.7% year over year to $4.37 billion, above expectations of $4.30 billion. IQVIA Reports Second-Quarter 2026 Results * Positive Sentiment: Full-year guidance was raised: IQVIA now expects fiscal 2026 earnings of $12.80 to $13.00 per share, above the prior consensus estimate of $12.57. Revenue guidance of $17.3 billion to $17.5 billion also reflects continued expansion in the business. IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised * Positive Sentiment: Demand indicators improved: Record R&D bookings, broad-based growth and a ballooning backlog suggest strong future revenue visibility and sustained demand for IQVIA's clinical-research and healthcare-intelligence services. IQVIA Stocks Rises on 2Q Gains, Ballooning Backlog * Positive Sentiment: Analysts became more bullish: JPMorgan raised its price target from $225 to $285 and assigned an "overweight" rating. Stifel lifted its target from $220 to $276 with a "buy" rating, while Robert W. Baird increased its target from $252 to $287 and maintained an "outperform" rating. These revisions indicate that analysts view the earnings beat and stronger outlook as durable catalysts. * Neutral Sentiment: IQVIA's new simplified organizational model is intended to improve collaboration and efficiency, but the financial benefits will depend on execution over time. The stock is also trading near its 52-week high, leaving less room for disappointment if growth or guidance momentum slows. Hedge funds weigh in on IQVIA. A number of institutional investors and hedge funds have recently modified their holdings of IQV. Vanguard Group Inc. increased its position in IQVIA by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company's stock valued at $4,429,426,000 after acquiring an additional 159,899 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company's stock valued at $982,272,000 after purchasing an additional 24,453 shares during the period. Boston Partners grew its stake in shares of IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company's stock valued at $923,276,000 after purchasing an additional 530,672 shares during the period. JPMorgan Chase & Co. increased its position in shares of IQVIA by 16.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company's stock valued at $856,468,000 after purchasing an additional 528,753 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of IQVIA by 15.3% in the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company's stock worth $526,891,000 after purchasing an additional 367,204 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors. IQVIA stock up 2.0%. NYSE:IQV opened at $247.84 on Thursday. The firm has a market cap of $41.36 billion, a P/E ratio of 30.75, a P/E/G ratio of 2.18 and a beta of 1.20. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.75 and a current ratio of 0.71. IQVIA has a fifty-two week low of $154.50 and a fifty-two week high of $251.36. The firm has a 50-day simple moving average of $192.00 and a two-hundred day simple moving average of $186.89. IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business's revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts predict that IQVIA will post 11.57 earnings per share for the current fiscal year. IQVIA announced that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's management believes its stock is undervalued. About IQVIA. IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real-world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets. IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I-IV), real-world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider IQVIA, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list. While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Yahoo Finance
Jul 29th, 2026
IQVIA shares jump 13% on strong Q2 results, raises full-year guidance to $17.5B revenue

IQVIA shares jumped 12.9% in morning trading after the clinical research company reported second-quarter results exceeding Wall Street expectations and raised its full-year guidance. The company posted revenue of $4.37 billion, up 8.7% year-on-year, beating estimates of $4.30 billion. Adjusted earnings per share reached $3.15, a 12.1% increase from the previous year, surpassing the consensus estimate of $3.03. Following the strong performance, IQVIA raised its full-year 2026 forecast. The company now projects revenue between $17.28 billion and $17.48 billion, with adjusted earnings per share ranging from $12.80 to $13.00. IQVIA shares are up 6.5% year-to-date and currently trade at $240.04, near their 52-week high of $244.29.

Yahoo Finance
Jul 28th, 2026
IQVIA reports $4.4B Q2 revenue, raises full-year guidance on strong R&D bookings

IQVIA reported second-quarter 2026 revenue of $4,368 million, up 8.7% year-over-year. The healthcare intelligence provider posted adjusted diluted earnings per share of $3.15, up 12.1%, and adjusted EBITDA of $994 million, up 9.2%. Commercial Solutions revenue reached $1,793 million, up 8.6%, whilst Research & Development Solutions revenue hit $2,575 million, up 8.8%. R&D Solutions generated record net new bookings of $3.15 billion, up 19%, with a 1.22x book-to-bill ratio. Operating cash flow rose 26% to $558 million. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted earnings per share.